New York State Common Retirement Fund Has $38.48 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

New York State Common Retirement Fund lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,225 shares of the company’s stock after purchasing an additional 3,820 shares during the period. New York State Common Retirement Fund owned 0.08% of IDEXX Laboratories worth $38,477,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $31,000. Armstrong Advisory Group Inc. raised its holdings in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the period. Salomon & Ludwin LLC bought a new position in shares of IDEXX Laboratories during the third quarter worth $35,000. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $30,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its position in shares of IDEXX Laboratories by 62.2% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 60 shares of the company’s stock valued at $38,000 after buying an additional 23 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $670.46 on Friday. The firm’s 50 day moving average is $705.35 and its 200-day moving average is $659.88. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $53.54 billion, a PE ratio of 53.17, a price-to-earnings-growth ratio of 3.61 and a beta of 1.67. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of several recent analyst reports. Morgan Stanley lifted their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. UBS Group boosted their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. Finally, Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $763.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.